Holen Sie sich die Stockscreener-App
1.24
0.00%
0.00
Vorhandelsmarkt:
1.24
Schlusskurs vom Vortag:
$1.24
Offen:
$1.24
24-Stunden-Volumen:
34,833
Relative Volume:
0.24
Marktkapitalisierung:
$85.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.22M
KGV:
-4.2509
EPS:
-0.2917
Netto-Cashflow:
$-4.60M
1W Leistung:
-4.62%
1M Leistung:
-3.13%
6M Leistung:
-12.68%
1J Leistung:
+5.98%
1-Tages-Spanne:
$1.22
$1.25
1-Wochen-Bereich:
$1.22
$1.34
52-Wochen-Spanne:
$1.05
$3.10
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Firmenname
Telomir Pharmaceuticals Inc
Sektor
Branche
Telefon
786-396-6723
Adresse
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.24 | 85.28M | 0 | -9.22M | -4.60M | -0.2917 |
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.30 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-21 | Eingeleitet | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten
Number of shareholders of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Price to earnings forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TELO) - TradingView
Telomir Pharmaceuticals Inc (TELO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Price to book forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Enterprise value to EBITDA forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Telomir Pharmaceuticals, Inc. develops Telomir-Zn to target intracellular metal balance in cancer cells - Traders Union
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - ACCESS Newswire
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Telomir Pharmaceuticals Inc (TELO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Telomir Pharmaceuticals Inc (TELO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Telomir Pharmaceuticals Inc (TELO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals to advance Telomir-Zn into clinical development for triple-negative breast cancer - Traders Union
Telomir Pharmaceuticals, Inc.: Telomir-Zn reverses insulin resistance in 14 days in new study - Traders Union
Exclusive: Telomir Pharmaceuticals secures FDA nod for its breast cancer therapy to advance into human study - MSN
Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data - TipRanks
Telomir publishes preclinical data on diabetes treatment candidate By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Restores Insulin Sensitivity in Type 2 Diabetes Model – Minichart - Minichart
Telomir publishes preclinical data on diabetes treatment candidate - Investing.com
Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial - Stock Titan
Experimental drug candidate reversed insulin resistance in 14 days — in fish - Stock Titan
Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Pre‑Revenue Development StageSubscription Growth Report - newsline.com
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Despite Positive Stock Reaction - newsline.com
Telomir Pharmaceuticals, Inc. reveals promising anti-tumor impact with Telomir-Zn in prostate cancer study - Traders Union
Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Cash Burn ConcernsConsensus Miss Rate - dars.gov.et
Telomir Pharmaceuticals (TELO) CFO Andriy Mushak files initial Form 3 - Stock Titan
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com UK
Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change - TipRanks
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com Australia
Telomir PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
Telomir Pharmaceuticals, Inc. Announces CFO Changes, Effective June 6, 2026 - marketscreener.com
Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO - Stock Titan
Telomir Pharmaceuticals (TELO) Edges Lower Amid Consolidation Near SupportTrend Following Picks - newsline.com
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
TELO Stock Price, Quote & Chart | TELOMIR PHARMACEUTICALS INC (NASDAQ:TELO) - ChartMill
TELOTelomir Pharmaceuticals Inc Stock Price and Quote - Finviz
Telomir Pharmaceuticals (TELO) Edges Lower, Testing Support Levels Amid Low VolumeProfitability Factor - The Legal Advocate
TELO Q4 2025 Earnings: EPS Misses Estimates by 292% as Cash Burn Continues; No Revenue ReportedEPS Surprise History - newsline.com
Telomir Pharmaceuticals (TELO) Consolidates Near $1.29 as Support and Resistance Levels TightenATR Stop - The Legal Advocate
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Significant EPS Miss Amid Pre-Clinical Stage OperationsNext Quarter Guidance - The Legal Advocate
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider Than Expected Loss Highlights Pre-Revenue ChallengesCFO Commentary Report - The Legal Advocate
Telomir Pharmaceuticals Q4 2025 Earnings: Wider Than Expected Loss Highlights Clinical-Stage ChallengesAnnual Financial Report - newsline.com
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - ACCESS Newswire
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Development-Stage ChallengesReturn On Capital - The Legal Advocate
Finanzdaten der Telomir Pharmaceuticals Inc-Aktie (TELO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.27%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):